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C l i n i c a l Reports 
Hyperviscosity Syndrome Complicating Rheumatoid Arthritis: 
Report of Two Additional Cases and Review of the Literature 
Michael R. Lovy, MD,* Mark C. Krane, MD,** Gilbert B. Bluhm, MD, 
Jeanne M. Riddle, PhD,*** and Paul D. Stein, MD**** 
*** 
A hyperviscosity syndrome developed in two patients 
with rheumatoid arthritis. Analytic ultracentrifugation 
of the sera from one patient demonstrated 225 com-
plexes. Intermediate, 22S, and 375 complexes were 
found in the second case. Platelet aggregometry and 
electron microscopy surveys of the platelet reactivity in 
one patient demonstrated inhibition of platelet reactiv-
ity caused by the presence ofthe high molecular weight 
complexes. These abnormalities, as well as the clinical 
bleeding, whole blood, and plasma viscosity, became 
normal after treatment. In vivo leukocytic function was 
studied with the Rebuck skin window technique, and 
phagosomal inclusions were observed in both the poly-
morphonuclear neutrophils and macrophages. 
Hyperviscosi ty syndrome is characterized by abnor-
malities affecting mult iple organ systems. Retinal hem-
orrhages, congestive heart failure, neurologic and hemo-
static abnormalities, and symptoms of anorexia, fatigue, 
and malaise are its manifestations. Although hyper-
gammaglobulinemia and elevated serum viscosity fre-
quently occur in patients with rheumatoid arthritis (1), 
they rarely reach levels necessary to produce hypervis-
cosity syndrome. 
Among the reported cases of hyperviscosity syndrome 
complicating rheumatoid arthritis (2-8), the specific 
immunoglobul in abnormality causing the increased vis-
cosity has varied. These abnormalities include polymers 
of IgG, which showed rheumatoid factor activity and 
cryoglobul in properties (2), IgG rheumatoid factor cir-
culating as a polyclonal 13S component (4), intermediate 
complexes formed by self-association of IgG rheuma-
toid factor molecules (6), and interaction of IgM rheu-
matoid factor with intermediate complexes (3,7). 
We have observed two additional patients with a hyper-
viscosity syndrome complicating rheumatoid arthritis. 
By the use of analytic ultracentri fugation, we were able 
to demonstrate 22S complexes in the sera of one patient 
and high molecular weight complexes in the other. 
These complexes were responsible for the hyperviscos-
ity. The bleeding diathesis was studied in each patient. I n 
the second patient, platelet aggregation and electron 
microscopic studies of the platelet reactivity suggested 
that intermediate and high molecular weight proteins 
were capable of altering platelet morphology and inter-
fering with in vitro platelet aggregation. 
Case Reports 
Case 1 
A 43-year-old black woman was admitted to Henry Ford Hospi-
tal in April 1969 because of anorexia, weight loss, fatigue, and 
frequent nosebleeds. She had been well until 1966, when she 
developed rheumatoid arthritis. She had numerous extra-
articular manifestations of rheumatoid arthritis, including sub-
cutaneous nodules, leg ulcers, a rheumatoid pleural effusion, 
and Sjogren's syndrome. 
On examination, there were decreased breath sounds at the 
base of the right lung, but no signs of active synovitis. Labora-
tory results included the following: hemoglobin 11.3 gm%, 
white blood cell count 4,000/mm3, with 44% polymorphonu-
clear cells, 3% eosinophils, 1% basophils, 15% lymphocytes. 
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32% atypical lymphocytes, and 5% monocytes. The erythro-
cytes showed marked rouleaux formation and numerous 
target cells. The platelet count was 442,000/mm^. The relative 
serum viscosity was 6.0 (normal 1.2-2) (9). Other laboratory 
parameters included: erythrocyte sedimentation rate (ESR) 
I m m / h r (Wintrobe method), lupus erythematosus (L.E.) cell 
preparation positive, strong homogeneous antinuclear factor, 
sodium 131 mEq/1, chloride 103 mEq/1, and C02 combining 
power 23 mEq/1 , total protein 8.8 g /d l , gamma globul in 5.0 
g /d l , IgG 4,640 mg/d l , IgM 2,347 mg/d l , and IgA 280 mg/d l . 
Examination of the bone marrow aspiration showed lympho-
cytosis, plasmacytosis, and slight eosinophil ia. The fo l lowing 
tests were either negative or normal: rheumatoid factor 
agglutination titer (10), urinalysis, metastatic survey, 24-hour 
urine for protein and immunoglobul in electrophoresis, serum 
cryoglobulins, sickle cell preparation, VDRL, total hemolytic 
complement, acute and convalescent viral antibody titers for 
pol io types 13, Echo 6, 9, and Coxsackie A-9, B l , 85, alkaline 
phosphatase, SCOT, and BSP retention. A survey of the plasma 
coagulation system showed that the Lee-White and plasma 
clott ing t ime, f ibr in stabilization factor, tests for circulating 
anticoagulants, and factor IX assay were normal. Before the 
patient received any therapy, coagulation studies showed 
abnormal results, with a bleeding t ime of eight minutes, acti-
vated partial thromboplast in t ime (APTT) of 98 seconds (con-
t ro l : 64 seconds), poor clot retraction, and a two-stage PIT 
assay for factor VIII of 74%. 
Dur ing her hospitalization, she developed bleeding of the 
gums, and cyclophosphamide (150 mg/day) was given orally. 
One week later, when she developed a pericardial fr ict ion rub 
and congestive heart fai lure, therapy with prednisone (60 
mg/day) was added to the treatment regimen. Wi th in one 
week she showed improvement of the congestive heart fail-
ure, her appetite returned, and bleeding ceased. Coagulation 
studies were normal three weeks after the cyclosphosphamide 
medication had been initiated. 
By June 1969, the patient was doing well on prednisone 10 
mg/day and cyclosphosphamide 50 mg every other day. The 
relative serum viscosity (11-13) was 1.75, total protein 6.8 
g m / d l , gamma globul in 1.6 g /d l , IgC 1,244 mg/d l , IgM 384 
mg /d l , IgA 153 mg/d l (14), and rheumatoid factor t i ter 1:320 
(15). Subsequent doses of medications and corresponding 
laboratory results were correlated (Fig. 1). 
Rheumatoid erosions o f t he interphalangeal joints, as demon-
strated radiographically, and rheumatoid factor activity in the 
synovial f luid were subsequently shown. Over the fo l lowing 
eight years, she had infrequent flares of arthritis. Treatment 
wi th indomethacin, aspirin, and prednisone (5 mg/day) was 
cont inued. She was last seen in the Rheumatology Clinic at 
Henry Ford Hospital in December 1978. 
Case 2 
A 60-year-old black man, with a six-year history of arthritis, was 
admitted to Henry Ford Hospital in September 1978 wi th head-
aches, episodic dizziness wi th an unsteady gait, dyspnea on 
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Fig.1 
Clinical and laboratory course of Case 1. DRAT = differential rheuma-
toid agglutination titer. Normal range for relative serum viscosity is 
1.2-2. 
exert ion, or thopnea, weakness, malaise, bleeding f rom his 
gums of two months' durat ion, and a weight lossof 15 pounds. 
In the month before he was admitted, he had noted increased 
morning stiffness and pain with swelling in his joints. 
He was in no acute distress, afebrile, his blood pressure was 
140/90 mm Hg, and he had a regular pulse of 100/min. His 
cheeks were erythematous. The retinal veins were distended, 
and there were scattered hemorrhages and exudates. He had 
only l imited movement of his jaw. He had bilateral contrac-
tures wi th crepitation and synovial thickening of the elbows 
and wrists, ulnar deviation of the hands with symmetrical 
deformity of the metacarpal phalangeal and proximal inter-
phalangeal joints, and a moderate effusion in the right knee. 
No subcutaneous nodules were present. 
The hemoglobin was 9.5 gm%, the white blood cell count 
5,800/mm^ wi th a normal dif ferential count except for an 
occasional atypical lymphocyte and mononuclear cells resem-
bl ing Mot t cells (Fig. 2A). The platelet count was201,000/mm3. 
The erythrocytes showed moderate rouleaux formation. Rheu-
matoid factor titer was 1:20,480 (15). Laboratory results are 
summarized in Tables I and 11. Serum protein electrophoresis 
demonstrated a gamma globul in peak of 5.9 g/d l with re-
stricted mobil i ty. A 24-hour urine collection contained a trace 
amount of free kappa chains, but no Bence-Jones protein. 
Bone marrow aspiration showed an atypical lymphocytosis and 
an increased number of plasma cells, some of which showed 
Russell bodies (Fig. 2B). Westergren sedimentation rate was 58 
mm/h r , antinuclear factor was positive; sodium 130 mEq/1, 
chlor ide 105 mEq/1, and CO2combining power was21 mEq/1. 
The fo l lowing tests were either normal or negative: urinalysis, 
L.E. cell preparation, serum cryoglobulins, hepatitis B antigen 
and antibody, heterophile antibody, serum uric acid, blood 
urea nitrogen, creatinine, b i l i rubin, SCOT, LDH, alkaline 
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phosphatase, calcium, phosphorus, and Schirmer's test. A PPD 
skin test was 15 mm. Peripheral T and B cell studies were 
normal, including E, EA, and EAC rosettes, surface immuno-
globulins, and mitogen stimulation with phytohemagglut inin, 
concanavalin A, and pokeweed mitogen (16,17). 
Coagulation studies showed that the bleeding t ime, Lee-White 
clott ing t ime, PT, APTT, f ibr inogen, prothrombin consump-
t ion, factor V l l l activity, and platelets were normal. Clot retrac-
t ion was 1+ at one hour and 2+ at two hours. There was in vitro 
resistance to platelet aggregation by standard tests with epi-
nephrine, adenosine diphosphate, and ristocetin (Fig. 3A). 
Initially, platelet reactivity as seen by transmission electron 
microscopy showed a decreased ability of individual platelets 
to extrude cytoplasmic pseudopodia (Fig. 4A). 
Chest radiographs showed a slight prominence of the pulmo-
nary vasculature and calcified hilar nodes. Extensive erosive 
changes of the interphalangeal joints were evident radio-
graphically. M-mode echocardiography and systolic t ime 
intervals demonstrated normal left ventricular funct ion. 
Plasmapheresis of 1000 cc of blood was performed on five 
consecutive days. The patient noted improvement in his dizzi-
ness, headaches, mucous membrane bleeding, and joint symp-
toms wi th in five days after the plasmapheresis was completed. 
Dur ing this t ime, the serum viscosity and gamma globul in 
concentrat ion decreased by more than 50% (Table I). The 
patient was discharged on prednisone (120 mg every other 
day) and 300 mg of isonicotine hydrazine (INH) daily. 
O n October 12, 1978, repeat platelet aggregation studies 
revealed normal aggregabllity (Fig. 3B). Platelet reactivity, 
evaluated by electron microscopy, showed a hyperactive 
response. The platelet differential count was dominated bythe 
spread type platelet, which accounted for 72% of the platelets 
(Fig. 4B). Clot retraction was 3+ at one hour and 4+ at two 
hours; the other coagulation tests were unchanged f rom pre-
vious studies. Peripheral T and B cell studies were again nor-
mal. Addi t iona l fo l low-up studies are shown in Tables I 
and I I . 
Over the next three months the patient remained asympto-
matic, apart f rom cont inued active synovitis. The dosage of 
prednisone was changed to once a day and gradually reduced 
to 15 mg/day over the next three months. On Apri l 10,1979, 
the patient suffered multiple gunshot wounds and died. 
Materials and Methods 
The relative viscosity was determined with one milliliter 
samples of sera using a red blood cell pipette viscometer 
at 37°C (9). Whole blood and plasma viscosities were 
measured with a Wells-Brookfield cone-plated viscome-
ter (Brookfield Engineering Laboratories, lnc,Stoughton, 
MA) at 37°C and a shear rate of 180 sec-\ 
Serum p r o t e i n e lec t rophores i s was p e r f o r m e d using a 
Sp inco cel l w i t h barb i ta l bu f fe r ( p H 8.6) at 22°C. Serum 
Fig. 2 
Case 2 
A. Mott cell and rouleaux formation in peripheral blood (X 1430); B. 
Plasma cell with Russell bodies from bone marrow (X1430); C. Macro-
phage; and D. Polymorphonuclear cell containing large cytoplasmic 
inclusions (arrows) from a Rebuck skin window lesion at 12 hours (X 
715). Leishman stain was used in all preparations. 
i m m u n o g l o b u l i n levels w e r e quan t i t a ted by the m i c r o -
d o u b l e d i f f us ion t e c h n i q u e (14). W e p e r f o r m e d i m m u -
n o e l e c t r o p h o r e t i c studies w i t h agarose gel us ing ant ise-
r u m m o n o s p e c i f i c fo r I gG , I g M , IgA, and lambda and 
kappa chains ( M e l o y , Sp r i ng f i e l d , V A ) . 
In t h e f irst pa t i en t , r h e u m a t o i d fac to r act iv i ty was 
d e t e r m i n e d by t h e sensi t ized sheep red b l o o d cel l 
agg lu t i na t i on test af ter t h e test se rum was absorbed 
o v e r n i g h t w i t h sheep red b l o o d cells (10). In the second 
pa t i en t , r h e u m a t o i d fac tor act iv i ty was measured by 
latex agg lu t i na t i on (15) ( D i f c o , D e t r o i t , M l ) . 
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Analytical ultracentrifugation was performed with a 
Beckman Mode l E ultracentrifuge. In Case l , sera stored 
at4°C was used and centrifuged at 60,000 rpm and 20°C. 
Sera f rom Case 2 obtained after the second day of plas-
mapheresis and one month later and then stored at 
-20°C was centrifuged at 57,692 rpm and 22°C in 12 mm 
double sector cells with sapphire windows. Samples 
were di luted 1:5 with 0.01 M potassium phosphate 
buffer (pH 7.3) containingO.15 M NaCl and dialyzed with 
the same solution overnight at 4°C. Aliquots were also 
di luted 1:5 with 0.05 M sodium acetate,0.15 M NaCl (pH 
4.0), and dialyzed with the same solution overnight at 
4°C. 
Agar gel f i l tration using both Bio-Gel A1.5 and A15 (Bio 
Rad, Richmond, CA) in 0.15 N NaCl was performed at 
neutral pH on plasma from Case 2 stored at 4°C. Protein 
concentration of all fractions obtained was estimated 
with optical density measurements at a wavelength of 
280 nm in a Beckman DU Spectrophotometer (Beck-
man Instruments, Fullerton, CA). Fractions containing 
protein were concentrated 30 times by vacuum dialysis 
and then analyzed for cryoprecipitates, rheumatoid fac-
tor activity, immunoelectrophoretic pattern, and im-
munoglobul in level using methods described above. 
The Bio-Gel columns were calibrated with molecular 
weight markers, including dextran blue and purif ied 
human IgM, IgG, and albumin. Serum deletion of IgM 
was prepared by dialysis of serum at 4°C against de ion-
ized water at neutral pFH. Afterwards, viscosity and 
immunoelectrophoretic patterns were determined. 
Platelet aggregation studies of Case 2 used citrated 
whole blood and were performed with a BIO/DATA 
Platelet Aggregation Profiler'^ using ristocetin (1.2 and 
2.0 mg/ml) adenosine diphosphate (0.8 mg/ml) , adren-
alin hydrochloride (1.0 mg/ml ) , and collagen. The plate-
let reactivity was determined by means of transmission 
electron microscopy (19). 
Skin windows were prepared as described by Rebuck 
and Crowley (20) by abrading a single site on the forearm 
and applying tetanus toxoid. Coverslips which served to 
collect the inflammatory exudate were changed at 6,12, 
24, and 36 hours. The adherent cells were stained with 
Leishman stain, and a differential count on 500 cells was 
performed on each coverslip. 
TABLE I 
Laboratory Results of Case 2 
Viscosity 
Relative Who le Plasma 
Hemato- Serum Blood* Total Gamma- Immunog lobu l i l i s * * 
crit (normal : (180 sec-^) Protein globulin IgG I g M IgA Rheumatoid 
Date Treatment (%) 1.2-2) (poise) (g/di) (mg/d l ) Faclor Titer 
Case 2 
9/9/78 none 29 8.0 10.1 5.9 3810 2230 310 20,480 
9/11 plasmapheresis 
9/12 plasmapheresis 32 .099 .059 8.0 2.25 2009 2260 237 
9/13 plasmapheresis 31 .088 .049 7,5 2.16 2359 2863 221 
9/14 plasmapheresis 33 .072 .039 
9/15 plasmapheresis 33 .063 .035 
9/19 prednisone 33 3.7 .064 .036 9.9 3.22 
(120 mg q.o.d.) 
10/12 prednisone 39 .044 .018 7h 2.66 1748 688 347 40,960 
(80 mg q.o.d.) 
12/6 prednisone .045 .013 7.2 1.86 1075 319 l i b 5,120 
(40 mg q.o.d.) 
1/12/79 prednisone 6.7 1.63 
(30 mg q.o.d.) 
3/22/79 prednisone 7.2 1.07 1,280 
(20 mg/day) 
*The viscosity of whole blood of normal subjects in our laboratory ranged between .037 and .048 poise, and plasma ranged between 
.013 and .017 poise (11). These values of whole blood viscosity are comparable to those reported by Rosenblatt, et al (12) using a shear 
rate of 230 sec"i; the values of plasma viscosity are comparable to those reported by Larcan, et al (13) using a shear rate of 230 sec"'. 
• •Normal values in our laboratory range f rom 600 to 1400 for IgG, 50 to 250 for I gM , and f rom 50 to 150 for IgA (14). 
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Results of Special Studies 
Analytical ultracentrifugation 
Schlieren patterns of serum obtained f rom Case 1 (Fig. 
5A) showed a 22S peak, which comprised approximately 
27% of the total protein, but no evidence of interme-
diate complexes was obtained. 
Schlieren patterns of serum obtained f rom Case 2 after 
two days of plasmapheresis showed fractions sediment-
ing at 4.19S, 7.79S, 13.37S, 22.13S, and 31.36S (Fig. 5B). 
Dialysis of the same serum in acid buffer resulted in the 
loss of intermediate and high molecular weight com-
plexes and an increase in 16.55S and 6.28S peaks (Fig. 5C). 
Serum obtained after one month of prednisone therapy 
also contained intermediate9.6S and 22S complexes, but 
they were present in smaller quantity (Fig. 5D). 
Serum immunoelectrophoresis (Case 2) 
Immunoelectrophoresis of pretreatment serum from 
Case 2 demonstrated precipitate around the origin and a 
double arc pattern of the precipitin line with all antisera 
used except anti-lgA (Fig. 6). This pattern indicates an 
IgG-IgM interaction. Serum depleted of IgM also failed 
to demonstrate a double arc pattern or precipitate 
around the origin. 
Gel f i l tration (Case 2) 
Separation of the immunoglobulins with a calibrated 
Bio-Gel A15 column (Fig. 7) revealed proteins ranging in 
size f rom 1.6 X 10= to 2.6 X 10^ molecular weight. Frac-
tions containing proteins had molecular weights of 2.6 X 
106, 2.2 X 106,9.0 X 105,4.5 X 105,2.8 X 10=, and 1.6 X 105. 
Fractions with the heaviest molecular weights contained 
more IgG than IgM. Rheumatoid factor activity, cryo-
precipitate, and abnormal double arc precipit in lines on 
immunoelectrophoresis were found exclusively in the 
IgM containing fractions. Small amounts of protein with 
molecular weight other than 9.0 X105 (IgM) and 1.6 X105 
(IgG) were present in the post-treatment serum. 
Viscosity determinations (Case 2) 
Plasma from Case 2 obtained after two days of plasma-
pheresis was separated into a fraction depleted of IgM 
and one with IgM alone. The viscosities of the whole 
plasma and these fractions were 0.059,0.010, and 0.0125 
poise, respectively. Neither fraction alone, therefore, 
could account for the hyperviscosity of the original 
plasma specimen. Dithiothreitol was added to the plasma 
sample in an amount needed to abolish all rheumatoid 
factor activity measured by latex agglutination. After 30 
minutes of incubation with dithiothreitol at room temper-
ature, the viscosity of the plasma decreased from 0.047 to 
0.023 poise. 
Assessment of Platelet Function 
Electron microscopic evaluation (Case 2) 
The ability of the platelets f rom the second patient to 
adhere to a standardized activating surface (Formvar 
film) and cohere together to form an aggregate was 
assessed in vitro before and after treatment. Before 
treatment, the platelet population showed a decreased 
capacity to extrude pseudopodia, as evidenced in the 
platelet differential count by the presence of an abnor-
mally increased percentage (34%) of the round type 
platelet. Pair-wise contrasts based on the percentage of 
the round type platelet differed significantly (p = 0.0001) 
f rom the mean percentage both for normal subjects 
(mean = 7%, range at ± 2 standard deviations, 0 to 20%) 
and for the post-treatment study on this patient (p = 
0.0005). 
Table II 
Complement Studies of Case 2 
C3 C4 
(mg/100 m l ; normal (mg/100 m l ; normal 
range: 100-200 mg/100 ml) range: 18-53 mg/100 ml) 
Date (beta 1C/1A) (plasma) 
9/12/78 61 10 
10/12/78 
12/6/78 154 17 
Total Hemolyt ic 
Complement (un i t s /m l ; 
normal range: 
80-170 uni ts/ml) 
85 
105 
Immune 
Complexes 
Titer* 
1:32 
1:8 
not detected 
•Detected by both monoclonal rheumatoid factor and Clq b inding assays (15). 
Circulat ing immune complexes and hypocomplementenia were detected when hyperviscosity syn-
drome was present, but they resolved when the syndrome was treated. 
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After treatment, the platelet differential count was dom-
inated by 72% of the spread type platelet, which is asso-
ciated with hyperactivity and is formed when cytoplasm 
spreads between adjacent extended pseudopodia. Sta-
tistical analysis showed that the percentage of the spread 
type platelet observed in the post-treatment study on 
this patient was significantly different (p = 0.001) both 
f rom normal subjects (normal mean = 8%, range ± 2 
standard deviations, 0 to 20%) and from the pretreat-
ment survey on this patient (p = 0.009). 
Rebuck skin windows (Case 2) 
Analysis of sequential coverslips revealed a normal pat-
tern of emigration for polymorphonuclear neutrophils 
and mononuclear cells. Some polymorphonuclear neu-
trophils and macrophages contained round, homo-
geneously darkly staining cytoplasmic inclusions that 
varied in size and number f romlO to12 per cell (Fig. 2C, 
2D). These cytoplasmic inclusions were present on the 
six- and 12-hour coverslips predominantly where there 
was little evidence of degenerating polymorphonuclear 
neutrophils, thus suggesting phagocytosis of exudative 
immune complexes at the lesion site. Macrophages from 
the 24- and 36-hour coverslips contained large amounts 
of melanin pigment in addit ion to the larger cytoplasmic 
inclusions, which simulated Mot t cells (Fig. 2A). 
RISTOCFPN 2.0 mg/ml 
ADP 
EPINEPHRME 
COLLAGEN 
FdSTOCETN 12 mg/ml 
JSEPTJEPHRNE 
ADP 
COU_AGEN 
Fig. 3 
Standard platelet aggregation by turbidometric determinations on 
Case 2: while there was clinical evidence of bleeding (A); and per-
formed after plasmapheresis and one month of prednisone therapy 
when clinical evidence of bleeding was absent (B). In vitro platelet 
aggregation in the patient's blood was inhibited during pretreatment 
(A) and normal post-treatment (B). 
Discussion 
Hyperviscosity syndrome in rheumatoid arthritis 
Both of our patients had seropositive rheumatoid arthri-
tis and signs and symptoms of the hyperviscosity syn-
drome. Neither our patients nor others reported with 
hyperviscosity syndrome and rheumatoid arthritis (2-8) 
have developed multiple myeloma, a previously de-
scribed occurrence with rheumatoid arthritis (21). 
Thefirst patient had numerous extra-articular manifesta-
tions of rheumatoid arthritis. Previously reported cases 
of rheumatoid arthritis complicated by hyperviscosity 
syndrome have shown nodules (3,5), Felty's syndrome 
(8,22), leg ulcers (2), and vasculitis characterized by nail 
fold infarcts and mesentericarteritis (7). A hyperviscosity 
syndrome has been reported in patients with Sjogren's 
syndrome both with (8,22) and wi thout (23-25) rheuma-
toid arthritis and associated with intermediate com-
plexes (23) and IgA-IgG complexes (25). 
In both of our patients we observed rouleaux formation 
and morphologic evidence of increased gamma glob-
ulin synthesis, including bone marrow plasmacytosis, 
Russell bodies, and circulating Mot t cells. Rouleaux 
formation (6,23) as well as bone marrow plasmacytosis 
and lymphocytosis (3-5,7,8,23-25) have been found in 
other cases of hyperviscosity syndrome associated with 
connective tissue diseases. Generalized lymphadeno-
pathy, perhaps another sign of lymphoid response to 
• 
A 
• 
B 
Fig. 4 
Platelet morphology studied wi th transmission electron microscopy. 
A. The pretreatment platelet preparat ion f rom Case 2 showed >30% of 
the round type platelet, indicat ing that pseudopodia format ion was 
inh ib i ted. B. After treatment, the number of the spread type platelet 
was abnormally increased (X 4300). 
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antigenic stimulus, has also been reported in patients 
w i th hyperviscosity and connect ive tissue disease 
(3,4,23,26). Previous studies have demonstrated that the 
bone marrow is the predominant source of immunoglob-
ulin product ion in both normal individuals (27,28) and 
those with monoclonal gammopathy (29). 
High molecular weight complexes 
In the first patient there was no evidence of the presence 
of intermediate complexes either by comparing the dif-
ference between the gamma globul in and IgG concen-
trations (30) or by analytical ultracentrifugation. 22S pro-
te in, composed of 19S IgM rheumatoid factor and 7S 
IgG, has been detected without intermediate complexes 
in patients with rheumatoid arthritis wi thout hypervis-
cosity syndrome (31-33) and correlates with high levels 
of rheumatoid factor and IgM (32). 22S protein was 
detected by analytical ultracentrifugation concommi-
tant with intermediate complexes in some cases of 
hyperviscosity syndrome associated with connective 
tissue disorders (6,23,26), but not in others (2,5,24). In 
cases where they were present (6,23,26), the 22S com-
plexes constituted a minor port ion of the total protein. 
In the second patient, IgM rheumatoid factor associated 
with intermediate and high molecular weight com-
plexes contr ibuted to the serum viscosity. The gel fi ltra-
A 
m 
c ^ m 
mm 
^ ' 1 • j 1^ 
1, e- . i ' 
h 
t ion done on plasma obtained before plasmapheresis 
(Fig. 7) showed that fractions containing IgM constituted 
most o f the immunoglobul in. Dithiothreitol reduces19S 
pentameric IgM into its7S monomericsubunits. Reduc-
t ion of the IgM with dithiothreitol resulted in a 44% 
reduction in plasma viscosity. The heaviest complexes 
contained more IgG than IgM and are likely to have 
included polymers of IgG rheumatoid factor. Evidence 
for IgG-IgM interaction included the double arc IgM 
and IgG precipit in lines, which disappeared in IgM-
deleted serum, and the presence of 22S and 31S com-
plexes that degraded into 6.2S and 16.55S peaks after 
acid treatment of the whole serum (Fig. 5). Although 
complexes of IgM rheumatoid factor interacting with 
intermediate IgG complexes wereconsidered important 
anti A 
patient 
anti K 
/ 
control 
anti IgM 
anti IgG 
anti Ig A 
Fig. 5 
Ultracentr i fugal patterns of who le serum f rom Casesi and 2. A. Case 1 
demonstrat ing 22S peak at 20 minutes (pH 7.3)- B. Case 2 serum after 
two days of plasmapheresis showing31S (arrow), 22S (arrowhead), and 
13S (open arrowhead) peaks at 22 minutes (pH 7.3)- C. Case 2 serum 
after two days of plasmapheresis showing 16S (arrow) and 6S (arrow-
head) peaks at 22 minutes (pH 4.0)- D. Case 2 serum one month later 
dur ing prednisone therapy showing 22S (arrow) peak and 9.7S (arrow-
head) peak at23 minutes (pH 7 3 ) . Bar angle is65° and sedimentat ion is 
f rom right to left. 
Fig. 6 
Serum immunoelectrophoresis of pretreatment serum (Case 2) per-
formed at room temperature. Double arc precipi t in lines are present 
wi th all antisera except ant i - lgA. Using the same antisera, there was no 
doub le arc precipi t in l ine wi th contro l sera. O n e such example is 
shown wi th anti-K antisera. 
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in the hyperviscosity in previously reported cases (3), 
complexes heavier than 19S were not present on analyti-
cal ultracentrifugation, as they were in our case, even 
after plasmapheresis of 2,000 cc. 
A mixed 19S-7S cryoglobulin (25) and one containing 
IgM, IgA, IgG, and C3 (7) were found in other cases of 
hyperviscosity syndrome and connective tissue disease. 
In the latter case, cryoprecipitate was found after gel 
f i l tration o f the plasma in the fraction containing most of 
the IgM and rheumatoid factor activity, as in oursecond 
patient. Cryoglobu lins were also detected in other cases 
of hyperviscosity syndrome and rheumatoid arthritis 
(2,8). Meltzer and Franklin detected the cryoglobulin in 
their patient only with di lut ion of the serum (2). They 
found that cryoprecipitation diminished when concen-
trations of macroglobulin exceeded 25 mg/ml . 
Platelet dysfunction 
Thrombocytopenia (3) and abnormal bleeding time (5) 
are the only findings indicative of platelet abnormalities 
reported previously in hyperviscosity syndrome due to 
either rheumatoid arthritis orSjogren's syndrome. Plate-
let dysfunction is an important cause of bleeding in 
dysproteinemias (34). A study of 62 patients with para-
proteinemia of various etiologies demonstrated a corre-
lation between hemorrhage and either abnormal bleed-
ing time or platelet adhesiveness (35). Platelet aggregation 
2,0-
PRE TREATMENT 
POST TREATMENT 
NORMAL 
20 30 40 50 60 70 
FRACTION NUMBER 
lgG> IgM IgM > IgG G?M IgG ONLY 
SO 
Fig. 7 
Gel f i l t rat ion through Bio-Gel A-15 done under identical condi t ions of 
sera f rom Case 2 and f rom normal . Post-treatment serum was obtained 
after one month of prednisone therapy. The relative propor t ion of 
immunog lobu l in according to m g / d l is shown below the correspond-
ing fraction numbers. Large amounts of abnormal ly present h igh 
molecular weight proteins (fractions 30-50) and intermediate molecu-
lar weight proteins (fractions 55-70) were present in the pretreatment 
sera. 
was not studied in these patients. In another study, plate-
let dysfunction, including ADP-induced aggregation, 
was found to depend on the paraprotein concentration 
(36). Abnormal platelet morphology as demonstrated by 
electron microscopy, bleeding t ime, and platelet factor 
111 activity have been associated with the coating of plate-
lets with macroglobulins in patients with Waldenstrom's 
macroglobulinemia (37). 
When the platelet population f rom Case2 was evaluated 
before treatment, the extrusion of pseudopodia by indi-
vidual platelets was clearly inhibited. An abnormally 
increased percentage of the round type platelet has 
been observed when platelets were present in an envi-
ronment which contained a high concentration of a 
large molecular weight substance such as the macroglo-
bulin of Waldenstrom's macroglobulinemia (38). Reduc-
t ion of the quantity of high molecular weight and inter-
mediate complexes fol lowing plasmapheresis probably 
explains the increased ability of the platelets to extrude 
pseudopodia and exhibit cytoplasmic spreading between 
adjacent pseudopodia.Thus, the post-treatment platelet 
differential count for Case 2 was dominated by the 
spread type rather than the round type platelet. Also, in 
a comparative survey of the platelet reactivity of patients 
with various rheumatic diseases, we reported that 57% of 
patients with rheumatoid arthritis have hyperactive 
platelets when they are surveyed with our standardized 
in vitro method (39). 
Cellular inclusions 
Some patients with paraproteinemia exhibit decreased 
leukocyte emigration when tested by the Rebuck skin 
window technique, which does not depend on parapro-
tein concentration (35). In that study, no mention was 
made of cytoplasmic inclusions similar to those seen in 
our second patient. Since this patient had large amounts 
of intermediate and high molecular weight complexes 
in the serum, it is likely that they were present in the 
inflammatory exudative f luid induced by the skin abra-
sion of the skin window and were subsequently phago-
cytized by both emigrating polymorphonuclear cells 
and macrophages. 
Intermediateand high molecularweightcomplexes(31) 
have been found in the sera of some rheumatoid arthri-
tis patients without hyperviscosity syndrome. Under 
normal conditions, the mononuclear phagocytic system, 
especially the liver (40-42), is capable of removing high 
molecular weight complexes from the blood. Fiowever, 
once the cells are saturated, immune complex levels 
may increase rapidly in the presence of constant produc-
t ion (42,43). Such a sequence of events could account for 
the rapid increase in gamma globul in level (1.7 g%) in 
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five days seen in Case 1 (Fig. 1). Despite the presumed 
saturation o f the mononuclear phagocytic system under 
condit ions of excessive immune complex load, emigrat-
ing mononuclear cells seen in the six- and 12-hour skin 
windowsof Case2 contained numerous inclusion bodies. 
Therapy 
Plasmapheresis was effective in rapidly relieving the 
symptoms of the second patient and has been in others 
with hyperviscosity syndrome also (44). It is particularly 
effective when the syndrome is due to high molecular 
weight proteins because they remain predominantly in 
the intravascular compartment (44). Because the rela-
t ionship between viscosity and paraprotein concentra-
t ion as well as hematocrit is nonlinear (45), a small 
change in protein concentration can cause whole blood 
and serum viscosity to drop significantly. The response 
to plasmapheresis may also be partly due to improve-
ment of mononuclear-phagocytic system function (46). 
Hlowever, patients with hyperviscosity syndrome and 
connective tissue disease have relapsed if steroids have 
not been cont inued after plasmapheresis (3-5,7). In 
these patients, low doses of prednisone have been effec-
tive in control l ing the immunoglobul in. 
Summary 
We are reporting on two patients with rheumatoid 
arthritis and hyperviscosity syndrome. Case 2 provided 
an opportuni ty to study the bleeding diathesis. For the 
first t ime we have documented that the basis of the 
bleeding in the hyperviscosity syndrome can be due to 
the interference of intermediate and high molecular 
weight complexes with platelet aggregation as well as 
inhibit ion of platelet surface activation and adhesion. 
A hyperviscosity syndrome associated with connective 
tissue disorders can be produced by different abnormal 
immunoglobul in complexes. The syndrome lacks char-
acteristics that distinguish it f rom the hyperviscosity syn-
dtome due to paraproteinemias. It can occur in patients 
with rheumatoid arthritis both with and wi thout extra-
articular manifestations or Sjogren's syndrome. Regard-
less of the type of immunoglobul in complex, plasma-
pheresis is indicated to relieve the symptoms of the 
hyperviscosity syndrome. Prednisone is recommended 
to depress immunoglobul in product ion. 
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